Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Sidney Street who wrote (3453)	10/29/2002 9:00:33 AM
From: Icebrg	Read Replies (1) \| Respond to of 10345

Sidney The two company's recent past seem to be relatively intertwined. According to Amarin's latest 20F Elan holds 23,8 % of Amarin's equity, which may be increased to 39,4 % upon conversion of some preferential shares Elan is holding. There are a number of persons with an Elan background working in or advising Amarin, one of whom is Amarin's Chairman Thomas Lynch (!). I have not been following Elan long enough to have a definite opinion on the subject, but somehow I have a feeling that Amarin was supposed to be used by Elan in a way similar to the development J/Vs. There is another US company Xcel Pharmaceuticals that was created for what seems to be a similar purpose. Although Elan was never able to have the latter fully financed and it was left hanging. Erik